IRLAB Therapeutics: IRL757 brings new flavour - ABG
Summarising an eventful H1'24
Many players in the Parkinson's therapy game...
...but IRLAB has a niche in symptomatic therapy.
Where do we stand today?
IRLAB has made important progress with its pipeline in the last six months. The lead programme mesdopetam passed the FDA end-of-Ph 2 meeting, paving the way for a pivotal Ph 3. Pirepemat's React-PD Ph 2b study reported an update on the patient's baseline characteristics, which enabled a reduction of the study size and the completion of enrolment in Q3'24e, followed by a top-line readout in Q1'25e. The IRL757 programme received funding from MJFF in late '23, financing Ph 1, which started in May'24. Recently IRLAB signed a deal with MSRD, financing IRL757's development through clinical PoC.
Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2024/6/irlab-therapeutics---irl757-brings-new-flavour/
